Agilent Technologies and Kreatech Diagnostics expand commercial relationship with new license and supply agreement

SANTA CLARA, CA., USA / Amsterdam, The Netherlands – Agilent Technologies Inc. and Kreatech Diagnostics today announced they are broadening their current business collaboration with an additional license and supply agreement for Kreatech’s patented ULS™ (Universal Linkage System) technology and products.

The new agreement allows US-based Agilent to incorporate Kreatech’s unique ULS™ technology into future products. Financial details are not disclosed.

Kreatech’s proprietary ULS™ is a direct chemical labeling technology featuring a fast two-step labeling procedure that allows the use of a broad range of fluorescent labels and haptens. It enables the labeling of nucleic acids irrespective of their length or composition. This aspect makes the technology ideally suited for reproducible and robust labeling of all species of DNA and RNA molecules.

“For several years, we have had a positive relationship with Agilent, through their Oligonucleotide Array-Based CGH product line that includes Kreatech ULS™ labeling kits, and we are especially pleased with the expansion of this commercial relationship” said Kees Moonen, CEO of Kreatech. “This new agreement underlines Kreatech’s unique labeling technology and will open the door for new opportunities for both companies. The new agreement fits very well into Kreatech’s commercial strategy to become a significant supplier of products for the US market”.

About Kreatech

Kreatech Diagnostics, based in Amsterdam, The Netherlands, develops and markets molecular diagnostics worldwide allowing health care providers to make informed decisions about the treatment of patients.

Kreatech’s REPEAT-FREE™ POSEIDON™ FISH products are the broadest available commercial portfolio of Fluorescent in Situ Hybridization probes for both diagnostic and research use.

Kreatech’s proprietary ULS™ labeling technology (Universal Linkage System) allows accurate (non-enzymatic) and fast labeling of DNA, RNA and proteins; one universal system compatible with all biological samples.

Kreatech has the support of leading professional life science investors: US-based Alafi Capital and Amsterdam-based Life Science Partners are initial investors in Kreatech.

Visit www.kreatech.com for more information.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company’s 18,500 employees serve customers in more than 110 countries. Agilent had net revenues of $5.4 billion in fiscal year 2010. Information about Agilent is available www.agilent.com.

< | >